NGAL and other markers of inflammation as competitive or complementary markers for depressive symptom dimensions in heart failure

2015 ◽  
Vol 16 (7) ◽  
pp. 536-541 ◽  
Author(s):  
Petrus J.W. Naudé ◽  
Paula M.C. Mommersteeg ◽  
Leonie Gouweleeuw ◽  
Ulrich L.M. Eisel ◽  
Johan Denollet ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sang R. Lee ◽  
Jun H. Heo ◽  
Seong Lae Jo ◽  
Globinna Kim ◽  
Su Jung Kim ◽  
...  

AbstractObesity is implicated in cardiovascular disease and heart failure. When fatty acids are transported to and not adequately oxidized in cardiac cells, they accumulate, causing lipotoxicity in the heart. Since hepatic progesterone receptor membrane component 1 (Pgrmc1) suppressed de novo lipogenesis in a previous study, it was questioned whether cardiac Pgrmc1 protects against lipotoxicity. Hence, we focused on the role of cardiac Pgrmc1 in basal (Resting), glucose-dominant (Refed) and lipid-dominant high-fat diet (HFD) conditions. Pgrmc1 KO mice showed high FFA levels and low glucose levels compared to wild-type (WT) mice. Pgrmc1 KO mice presented low number of mitochondrial DNA copies in heart, and it was concomitantly observed with low expression of TCA cycle genes and oxidative phosphorylation genes. Pgrmc1 absence in heart presented low fatty acid oxidation activity in all conditions, but the production of acetyl-CoA and ATP was in pronounced suppression only in HFD condition. Furthermore, HFD Pgrmc1 KO mice resulted in high cardiac fatty acyl-CoA levels and TG level. Accordingly, HFD Pgrmc1 KO mice were prone to cardiac lipotoxicity, featuring high levels in markers of inflammation, endoplasmic reticulum stress, oxidative stress, fibrosis, and heart failure. In vitro study, it was also confirmed that Pgrmc1 enhances rates of mitochondrial respiration and fatty acid oxidation. This study is clinically important because mitochondrial defects in Pgrmc1 KO mice hearts represent the late phase of cardiac failure.


2011 ◽  
Vol 17 (9) ◽  
pp. 755-763 ◽  
Author(s):  
Rebecca L. Dekker ◽  
Terry A. Lennie ◽  
Nancy M. Albert ◽  
Mary K. Rayens ◽  
Misook L. Chung ◽  
...  

2011 ◽  
Vol 42 (1) ◽  
pp. 51-60 ◽  
Author(s):  
S. Bekke-Hansen ◽  
M. Trockel ◽  
M. M. Burg ◽  
C. Barr Taylor

BackgroundDepression following myocardial infarction (MI) independently increases risk for early cardiac morbidity and mortality. Studies suggest that somatic, but not cognitive, depressive symptoms are responsible for the increased risk. However, the effects of somatic depressive symptoms at follow-up, after sufficient time has elapsed to allow for physical recovery from the initial infarction, are not known. Our aim was to examine the relationship between cognitive and somatic depressive symptom dimensions at baseline and 12 months post-MI and subsequent mortality and cardiovascular morbidity.MethodPatients were 2442 depressed and/or socially isolated men and women with acute MI included in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) clinical trial. We used principal components analysis (PCA) of the Beck Depression Inventory (BDI) items to derive subscales measuring cognitive and somatic depressive symptom dimensions, and Cox regression with Bonferroni correction for multiple testing to examine the contribution of these dimensions to all-cause mortality, cardiovascular mortality, and first recurrent non-fatal MI.ResultsAfter adjusting for medical co-morbidity and Bonferroni correction, the somatic depressive symptom dimension assessed proximately following MI did not significantly predict any endpoints. At 12 months post-MI, however, this dimension independently predicted subsequent all-cause [hazard ratio (HR) 1.43, 95% confidence interval (CI) 1.13–1.81] and cardiovascular mortality (HR 1.60, 95% CI 1.17–2.18). No significant associations were found between the cognitive depressive symptom dimension and any endpoints after Bonferroni correction.ConclusionsSomatic symptoms of depression at 12 months post-MI in patients at increased psychosocial risk predicted subsequent mortality. Psychosocial interventions aimed at improving cardiac prognosis may be enhanced by targeting somatic depressive symptoms, with particular attention to somatic symptom severity at 12 months post-MI.


2016 ◽  
Vol 57 ◽  
pp. 144-150 ◽  
Author(s):  
Paula M.C. Mommersteeg ◽  
Regien G. Schoemaker ◽  
Petrus J.W. Naudé ◽  
Ulrich L.M. Eisel ◽  
Ingrid M. Garrelds ◽  
...  

2009 ◽  
Vol 66 (5) ◽  
pp. 499 ◽  
Author(s):  
Sarah E. Linke ◽  
Thomas Rutledge ◽  
B. Delia Johnson ◽  
Viola Vaccarino ◽  
Vera Bittner ◽  
...  

2006 ◽  
Vol 26 (4) ◽  
pp. 260 ◽  
Author(s):  
Paula R. Pullen ◽  
Walter R. Thompson ◽  
Paul D'Amato ◽  
Regina Cuchapin ◽  
Rekha G. Menon ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document